Clinical Trial Update: Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Exenatide for gastrointestinal motor function and permeability in Short Bowel Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Mayo Clinic | Conditions: Short Bowel Syndrome | Phase 4 | Status: WITHDRAWN